Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor

IF 2.4 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2024-09-15 DOI:10.1007/s10147-024-02622-z

Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano, Yusuke Ishigami, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda

{"title":"Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor","authors":"Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano, Yusuke Ishigami, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda","doi":"10.1007/s10147-024-02622-z","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Immune checkpoint inhibitors (ICIs) have been approved as first-line therapy for advanced non-small cell lung cancer (NSCLC). The probiotic MIYAIRI 588 can potentially improve the outcomes of patients with advanced NSCLC treated with ICI. However, the impact of other probiotics on ICI-treatment efficacy remains unclear. Thus, we aimed to clarify the association between BIO-three use and treatment outcomes in patients with advanced NSCLC treated with ICI.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This retrospective study included patients aged ≥ 18 years with advanced or recurrent NSCLC who had received ICI monotherapy or ICI plus chemotherapy. Concomitant therapy with probiotic bacteria was defined as receiving it within 180 days before ICI therapy.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Here, 289 patients were enrolled, including 23 (8.0%) receiving BIO-three. In the multivariable analysis, the progression-free survival (PFS) and overall survival (OS) of patients receiving BIO-three tended to be longer than those of patients not receiving probiotic therapy (PFS, hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.43–1.30; <i>p</i> = 0.33; OS, HR 0.69; 95% CI 0.37–1.28; <i>p</i> = 0.24). After propensity score matching with weighted adjustment, patients receiving BIO-three tended to have prolonged PFS (median PFS [range] 7.6 months [2.6–17.4] vs 3.2 months [1.6–7.0]; HR 0.53; 95% CI 0.25–1.12; <i>p</i> = 0.09) and OS (median OS [range] 25.6 months [10.8–not reached] vs 10.9 months [7.3–not reached]; HR 0.57; 95% CI 0.24–1.36; <i>p</i> = 0.20) than those not receiving probiotic therapy.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study suggests the prognostic impact of concomitant BIO-three use in patients with advanced NSCLC on ICI treatment.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":"155 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02622-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Immune checkpoint inhibitors (ICIs) have been approved as first-line therapy for advanced non-small cell lung cancer (NSCLC). The probiotic MIYAIRI 588 can potentially improve the outcomes of patients with advanced NSCLC treated with ICI. However, the impact of other probiotics on ICI-treatment efficacy remains unclear. Thus, we aimed to clarify the association between BIO-three use and treatment outcomes in patients with advanced NSCLC treated with ICI.

Methods

This retrospective study included patients aged ≥ 18 years with advanced or recurrent NSCLC who had received ICI monotherapy or ICI plus chemotherapy. Concomitant therapy with probiotic bacteria was defined as receiving it within 180 days before ICI therapy.

Results

Here, 289 patients were enrolled, including 23 (8.0%) receiving BIO-three. In the multivariable analysis, the progression-free survival (PFS) and overall survival (OS) of patients receiving BIO-three tended to be longer than those of patients not receiving probiotic therapy (PFS, hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.43–1.30; p = 0.33; OS, HR 0.69; 95% CI 0.37–1.28; p = 0.24). After propensity score matching with weighted adjustment, patients receiving BIO-three tended to have prolonged PFS (median PFS [range] 7.6 months [2.6–17.4] vs 3.2 months [1.6–7.0]; HR 0.53; 95% CI 0.25–1.12; p = 0.09) and OS (median OS [range] 25.6 months [10.8–not reached] vs 10.9 months [7.3–not reached]; HR 0.57; 95% CI 0.24–1.36; p = 0.20) than those not receiving probiotic therapy.

Conclusion

This study suggests the prognostic impact of concomitant BIO-three use in patients with advanced NSCLC on ICI treatment.

Abstract Image

查看原文本刊更多论文

在接受免疫检查点抑制剂治疗的晚期或复发性非小细胞肺癌患者中同时使用 BIO-three 的临床影响

背景免疫检查点抑制剂（ICIs）已被批准作为晚期非小细胞肺癌（NSCLC）的一线疗法。益生菌 MIYAIRI 588 有可能改善接受 ICI 治疗的晚期 NSCLC 患者的预后。然而，其他益生菌对 ICI 治疗效果的影响仍不清楚。方法这项回顾性研究纳入了年龄≥ 18 岁、接受过 ICI 单药治疗或 ICI 加化疗的晚期或复发性 NSCLC 患者。结果共纳入289例患者，其中23例（8.0%）接受了BIO-three治疗。在多变量分析中，接受 BIO-three 治疗的患者的无进展生存期（PFS）和总生存期（OS）往往长于未接受益生菌治疗的患者（PFS，危险比 [HR] 0.75；95% 置信区间 [CI] 0.43-1.30；P = 0.33；OS，HR 0.69；95% CI 0.37-1.28；P = 0.24）。经过倾向得分匹配和加权调整后，接受 BIO-three 治疗的患者的 PFS（中位 PFS [range] 7.6 个月 [2.6-17.4] vs 3.2 个月 [1.6-7.0]；HR 0.53；95% CI 0.25-1.12；p = 0.09）和 OS（中位 OS [range] 25.6 个月 [10.8-未达标] vs 10.9个月[7.3-未达标]；HR 0.57；95% CI 0.24-1.36；P = 0.20）。结论这项研究表明，在接受ICI治疗的晚期NSCLC患者中同时使用BIO-three对预后有影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.